Thiazolidinediones, insulin resistance and obesity: Finding a balance.
about
Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information SystemRosiglitazone improves survival and hastens recovery from pancreatic inflammation in obese micePharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.Pioglitazone therapy in mouse offspring exposed to maternal obesityPPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.PPARdelta Agonism for the Treatment of Obesity and Associated Disorders: Challenges and OpportunitiesAntioxidant supplemention in the treatment of skeletal muscle insulin resistance: potential mechanisms and clinical relevance.A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatmentLT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.Environmental endocrine disruptors promote adipogenesis in the 3T3-L1 cell line through glucocorticoid receptor activation.Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome.The safety of thiazolidinediones.SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.Medication use for the treatment of diabetes in obese individuals.Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.Prunus mume leaf extract lowers blood glucose level in diabetic mice.Effect of 2,4-thiazolidinedione on limousin cattle growth and on muscle and adipose tissue metabolism.Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: post hoc analysis of a randomized, 52-week, open-label, parallel-group trialEfficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.Palmitate-induced insulin resistance is attenuated by Pioglitazone and EGCG through reducing the gluconeogenic key enzymes expression in HepG2 cells.
P2860
Q33288486-AD12D77F-C5E9-4FD5-A1D5-83F9B9FDF70AQ34345441-05D78AFD-1801-45A1-8C8F-71E05B9A5748Q34628781-1137249E-F675-4D19-8B69-F3C8EFEF9B03Q36724356-E6551FB0-4857-4352-A863-11B2BE37687AQ36772391-0F1BA439-7DA9-4FF9-B398-5199EB41A569Q36959065-F17A8F69-04C9-409B-B5C6-5E531E719467Q37112535-F909F798-3F46-4D97-A46A-EE4FE19076FDQ37319128-7745619B-3B62-4315-AE2B-CE71C2C424F2Q37622614-496B8A2D-ACE2-4C10-B4E8-9407C8E7EAE6Q37642820-2BC6D74F-C24E-4298-A808-76D14B30D72DQ37690751-BAA06498-83E4-4A76-BCBB-A15F3816D4DCQ37724195-801E4875-376B-49AC-87EB-2349BD39D35EQ37786147-27FE234A-262C-45AE-AC4D-B08A9BD83F04Q37848841-27F12CAD-2A8A-452E-9CEC-3276A3AB072EQ37872125-75B17297-7253-4AF6-A5D5-9C4E18AD74FEQ39304674-5F2D1DC3-240D-4BF6-AA34-2F66DA05B6B6Q39404106-0249DC5D-93D7-4E5F-81BA-7E90E76F1023Q39971778-A873C154-F6A2-4C55-B73A-93205D6D7DB5Q42413296-53610FF7-8527-4F74-80B4-71EA6FBDB5CCQ42695296-104EFBB1-E027-4C7A-BBB5-6EEFFDE2462EQ47995019-364F520C-7561-436D-9A85-703E1A142084Q49837836-E55F5655-2D03-4E47-97B6-3EA5A977846B
P2860
Thiazolidinediones, insulin resistance and obesity: Finding a balance.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Thiazolidinediones, insulin resistance and obesity: Finding a balance.
@ast
Thiazolidinediones, insulin resistance and obesity: Finding a balance.
@en
type
label
Thiazolidinediones, insulin resistance and obesity: Finding a balance.
@ast
Thiazolidinediones, insulin resistance and obesity: Finding a balance.
@en
prefLabel
Thiazolidinediones, insulin resistance and obesity: Finding a balance.
@ast
Thiazolidinediones, insulin resistance and obesity: Finding a balance.
@en
P1476
Thiazolidinediones, insulin resistance and obesity: Finding a balance
@en
P2093
P304
P356
10.1111/J.1742-1241.2006.01128.X
P50
P577
2006-10-01T00:00:00Z